254 related articles for article (PubMed ID: 15748883)
21. Requirement of activated Cdc42-associated kinase for survival of v-Ras-transformed mammalian cells.
Nur-E-Kamal A; Zhang A; Keenan SM; Wang XI; Seraj J; Satoh T; Meiners S; Welsh WJ
Mol Cancer Res; 2005 May; 3(5):297-305. PubMed ID: 15886301
[TBL] [Abstract][Full Text] [Related]
22. Role of the Rap1 GTPase in astrocyte growth regulation.
Apicelli AJ; Uhlmann EJ; Baldwin RL; Ding H; Nagy A; Guha A; Gutmann DH
Glia; 2003 May; 42(3):225-34. PubMed ID: 12673829
[TBL] [Abstract][Full Text] [Related]
23. Role of RHOB in the antiproliferative effect of glucocorticoid receptor on macrophage RAW264.7 cells.
Wang X; Chen Y; Wang Y; Zhu X; Ma Y; Zhang S; Lu J
J Endocrinol; 2009 Jan; 200(1):35-43. PubMed ID: 18840672
[TBL] [Abstract][Full Text] [Related]
24. RhoB prenylation is driven by the three carboxyl-terminal amino acids of the protein: evidenced in vivo by an anti-farnesyl cysteine antibody.
Baron R; Fourcade E; Lajoie-Mazenc I; Allal C; Couderc B; Barbaras R; Favre G; Faye JC; Pradines A
Proc Natl Acad Sci U S A; 2000 Oct; 97(21):11626-31. PubMed ID: 11027361
[TBL] [Abstract][Full Text] [Related]
25. In vivo restoration of RhoB expression leads to ovarian tumor regression.
Couderc B; Pradines A; Rafii A; Golzio M; Deviers A; Allal C; Berg D; Penary M; Teissie J; Favre G
Cancer Gene Ther; 2008 Jul; 15(7):456-64. PubMed ID: 18340357
[TBL] [Abstract][Full Text] [Related]
26. Ras effector pathways modulate scatter factor-stimulated NF-kappaB signaling and protection against DNA damage.
Fan S; Meng Q; Laterra JJ; Rosen EM
Oncogene; 2007 Jul; 26(33):4774-96. PubMed ID: 17297451
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Ras-induced cancers by the F-actin cappers tensin and chaetoglobosin K, in combination with the caspase-1 inhibitor N1445.
Tikoo A; Cutler H; Lo SH; Chen LB; Maruta H
Cancer J Sci Am; 1999; 5(5):293-300. PubMed ID: 10526670
[TBL] [Abstract][Full Text] [Related]
28. Activated ras regulates the proliferation/apoptosis balance and early survival of developing micrometastases.
Varghese HJ; Davidson MT; MacDonald IC; Wilson SM; Nadkarni KV; Groom AC; Chambers AF
Cancer Res; 2002 Feb; 62(3):887-91. PubMed ID: 11830548
[TBL] [Abstract][Full Text] [Related]
29. Disrupting the transforming activity of shrimp ras(Q(61)K) by deleting the CAAX box at the C-terminus.
Huang CF; Chen CH; Chuang NN
J Exp Zool; 2001 Jun; 289(7):441-8. PubMed ID: 11351331
[TBL] [Abstract][Full Text] [Related]
30. Beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis.
Bertotti A; Comoglio PM; Trusolino L
Cancer Res; 2005 Dec; 65(23):10674-9. PubMed ID: 16322210
[TBL] [Abstract][Full Text] [Related]
31. Regulation of Par-4 by oncogenic Ras.
Vasudevan KM; Ranganathan P; Rangnekar VM
Methods Enzymol; 2006; 407():422-42. PubMed ID: 16757343
[TBL] [Abstract][Full Text] [Related]
32. Oncogenic Ras-mediated downregulation of Clast1/LR8 is involved in Ras-mediated neoplastic transformation and tumorigenesis in NIH3T3 cells.
Ryu SH; Kim KH; Kim HB; Kim MH; Kim NH; Kang Y; Hyun JW; Seo HJ; Jun JY; You HJ
Cancer Sci; 2010 Sep; 101(9):1990-6. PubMed ID: 20550525
[TBL] [Abstract][Full Text] [Related]
33. Repression of BCL2 by the tumor suppressor activity of the lysyl oxidase propeptide inhibits transformed phenotype of lung and pancreatic cancer cells.
Wu M; Min C; Wang X; Yu Z; Kirsch KH; Trackman PC; Sonenshein GE
Cancer Res; 2007 Jul; 67(13):6278-85. PubMed ID: 17616686
[TBL] [Abstract][Full Text] [Related]
34. Regulation of the expression of tropomyosins and actin cytoskeleton by ras transformation.
Prasad GL
Methods Enzymol; 2006; 407():410-22. PubMed ID: 16757342
[TBL] [Abstract][Full Text] [Related]
35. Farnesylated RhoB prevents cell cycle arrest and actin cytoskeleton disruption caused by the geranylgeranyltransferase I inhibitor GGTI-298.
Allal C; Pradines A; Hamilton AD; Sebti SM; Favre G
Cell Cycle; 2002; 1(6):430-7. PubMed ID: 12548020
[TBL] [Abstract][Full Text] [Related]
36. Transformation of NIH/3T3 to anchorage independence by H-ras is accompanied by loss of suppressor activity.
Tolsma SS; Cohen JD; Ehrlich LS; Bouck NP
Exp Cell Res; 1993 Apr; 205(2):232-9. PubMed ID: 8482334
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells.
Calleros L; Sánchez-Hernández I; Baquero P; Toro MJ; Chiloeches A
Carcinogenesis; 2009 Oct; 30(10):1670-7. PubMed ID: 19700418
[TBL] [Abstract][Full Text] [Related]
38. Immortalized fibroblasts from NF-kappaB RelA knockout mice show phenotypic heterogeneity and maintain increased sensitivity to tumor necrosis factor alpha after transformation by v-Ras.
Gapuzan ME; Schmah O; Pollock AD; Hoffmann A; Gilmore TD
Oncogene; 2005 Sep; 24(43):6574-83. PubMed ID: 16027734
[TBL] [Abstract][Full Text] [Related]
39. Osteopontin is an oncogenic Vav1- but not wild-type Vav1-responsive gene: implications for fibroblast transformation.
Schapira V; Lazer G; Katzav S
Cancer Res; 2006 Jun; 66(12):6183-91. PubMed ID: 16778192
[TBL] [Abstract][Full Text] [Related]
40. Dominant-negative Rac1 suppresses Ras-induced apoptosis possibly through activation of NFkappaB in Ha-ras oncogene-transformed NIH/3T3 cells.
Chou CK; Liang KH; Tzeng CC; Huang GC; Chuang JI; Chang TY; Liu HS
Life Sci; 2006 Mar; 78(16):1823-9. PubMed ID: 16274703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
